TGTX vs UMBF Comparison

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.